samedan logo
 
 
spacer
home > epc > winter 2018 > marking safety
PUBLICATIONS
European Pharmaceutical Contractor

Marking Safety

“Sepsis is the most preventable cause of death” (1), and every hour it is not diagnosed will increase the probability of killing the patient by 7%; thus, recognising the early signs and symptoms is crucial. Severe sepsis is the leading cause of death in the noncoronary intensive care unit, with mortality rates between 30-50%.

According to Dr Adam Linder, “approximately one in five patients with sepsis who are admitted to hospital are at risk of developing severe sepsis within the first 24 hours” (2). Furthermore, it is also the biggest killer of children under five worldwide. Konrad Reinhart notes that 6 million babies from third-world countries and 10,000 of mothers die from the condition every year (1).

As sepsis often impacts the elderly (usually when they have some other condition), it is perhaps less talked about, but it also affects children. With such susceptible groups as these, anything that raises awareness among medical staff of the signs, symptoms, and dangers can only be a good thing.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Professor Christene Leiper attended Sydney University, RMIT Melbourne, and Bond University in Australia and achieved a Professor of Medicine and Life Sciences at Bond University Queensland in 2006. She also undertook research at Edinburgh University, Scotland, as part of her PhD. Christene has been a Principal Investigator for clinical trials, which enables her to operate across many disciplinary boundaries within clinical research in a coherent and productive manner. In 2007, she was appointed Director of Research at a Scottish CRO, which in turn, led her to start her own CRO, Onorach, in 2009.
spacer
Professor Christene Leiper
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Datwyler celebrates official opening of its new production plant with First Line standard in Middletown, Del

• The new facility in Middletown, Del., is Datwyler’s third facility with First Line standard which will be catering to the markets in North and South America • Approximately 120 jobs will be created, with the majority staffed from the local community • With the Middletown facility, Datwyler will be able to increase its global First Line production by 50 percent by 2020 • First Line is specially designed to manufacture biotech and pharmaceutical elastomer components in a fully integrated good manufacturing practice (GMP) environment
More info >>

White Papers

High-tech Packaging for High-tech Medicine

West Pharmaceutical Services, Inc.

As more biologics and biosimilars come on to the global pharmaceutical market, they can and will present unique packaging and containment challenges. For materials that are sensitive to glass or that may require larger-dose volumes or custom configurations, cyclic olefin polymers may offer a solution. These novel materials for drug container closure systems can provide a needed alternative to traditional glass containment systems for advanced therapeutics.
More info >>

 
Industry Events

SMi Presents the 11th Adaptive Designs in Clinical Trials Conference 2019

1-2 April 2019, Holiday Inn Kensington Forum, London

SMi Group are proud to announce the 11th annual Adaptive Designs in Clinical Trials conference and exhibition will return to London from the 1st – 2nd April 2019. With the growing popularity in use and acceptance of adaptive designs in clinical trials - demonstrated most recently with the new FDA draft guidance on adaptive designs – there is a pressing need for a forum which explores this increasingly normalized medical methodology.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement